Douglas A. Whittington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Douglas A. Whittington has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Jannik Nørgaard Andersen
Tango Therapeutics, Boston, Massachusetts
146 shared publications - Yi Yu
Tango Therapeutics, Boston, USA
129 shared publications - John P. Maxwell
Tango Therapeutics (United States) 2 Boston, MA
121 shared publications - Binzhang Shen
Tango Therapeutics, Boston, Massachusetts
113 shared publications - Samuel R. Meier
Tango Therapeutics, Boston, Massachusetts
112 shared publications - William D. Mallender
Tango Therapeutics (United States) 2 Boston, MA
108 shared publications
Latest Publications
- Open Access
- 12 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302  (11)
Genetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer
- 12 September 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302  (11)
Open AccessGenetic and biochemical screens identify MGAT1 as a druggable glycosyltransferase target in STK11-mutant lung cancer
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Immune profiling in HT29 humanized mouse model
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Immune profiling in HT29 humanized mouse model
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is a potent, reversible, and selective EHMT1/2 inhibitor.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is a potent, reversible, and selective EHMT1/2 inhibitor.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Immune profiling in HT29 humanized mouse model
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Immune profiling in HT29 humanized mouse model
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 potently induces CXCL10 secretion.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 potently induces CXCL10 secretion.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is well tolerated in mouse studies.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is well tolerated in mouse studies.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
EHMT1/2 knockout induces a broad interferon signature.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
EHMT1/2 knockout induces a broad interferon signature.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is a selective inhibitor of EHMT1/2.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
TNG917 is a selective inhibitor of EHMT1/2.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Transcriptomic profiling in CT26 syngeneic mouse model
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Transcriptomic profiling in CT26 syngeneic mouse model
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Crystallography data collection and refinement statistics
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Antitumor Immunity and Immunotherapy Efficacy
Crystallography data collection and refinement statistics